Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus placebo with adjuvant chemotherapy with or without radiotherapy after curative surgery for high-risk newly diagnosed endometrial cancer
CTR20211275Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in endometrial cancer (EC), endometrial carcinosarcoma, sponsored by Merck & Co.. Started Jul 2021; status: active.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on CTR20211275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211275.